运用网状Meta分析方法比较不同针灸疗法治疗冠心病稳定型心绞痛(SAP)的临床疗效。计算机检索PubMed、Web of Science、Cochrane Library、中国期刊全文数据库(CNKI)、万方数据知识服务平台(Wanfang)、维普资讯中文期刊服务平台(VIP)2002...运用网状Meta分析方法比较不同针灸疗法治疗冠心病稳定型心绞痛(SAP)的临床疗效。计算机检索PubMed、Web of Science、Cochrane Library、中国期刊全文数据库(CNKI)、万方数据知识服务平台(Wanfang)、维普资讯中文期刊服务平台(VIP)2002年5月1日至2022年5月1日针灸治疗冠心病SAP的随机对照试验文献,运用Cochrane 5.3偏倚风险评估工具进行质量评价,Stata 13.1进行网状Meta分析。共纳入29篇文献,涉及针刺、穴位贴敷、艾灸等针灸疗法。穴位贴敷、艾灸、针刺、皮内针联合常规西药治疗改善心绞痛有效率优于单独常规西药治疗(P<0.05),且穴位贴敷联合常规西药治疗成为最优治疗方法的可能性大[曲线下面积(SUCRA)=0.711,P<0.05]。针刺联合常规西药治疗改善心电图有效率优于常规西药治疗(P<0.05),且针刺联合常规西药治疗成为最优治疗方法可能性大(SUCRA=0.800,P<0.05)。针刺、穴位贴敷、艾灸、皮内针联合常规西药治疗均能提高冠心病SAP的临床疗效,但在不同结局指标下,最佳的治疗方式可能有所区别,还需更多多中心、大样本的随机对照试验对结果加以验证。展开更多
Objective： To investigate the efficacy of integrated Chinese and Western medicine（IM） in the treatment of metastatic colorectal cancer（m CRC） in a cohort study.Methods： The survival outcome of patients receiving...Objective： To investigate the efficacy of integrated Chinese and Western medicine（IM） in the treatment of metastatic colorectal cancer（m CRC） in a cohort study.Methods： The survival outcome of patients receiving IM was compared with that of patients receiving Western medicine alone.The study design was adopted with ＂continuous administration of Chinese medicine for 3 months＂ as the exposure factor.Patients who met this exposure factor were assigned to the IM cohort（Group A,110 patients）.Patients who did not meet this exposure factor were assigned to the Western medicine cohort（Group B,225 patients）.The overall survival（OS）,progression-free survival（PFS）,and 1 st year,2 nd year,and 3 rd year survival in the two cohorts were compared.Results： The median OS in Group A and B were 18 months [95% confidence interval（CI） 15-21] and 16 months（95% CI 14-18）,respectively,and the median PFS in Group A and B were 6 months（95% CI 4-7） and 5 months（95% CI 4-6）,respectively.No statistically significant differences were observed between the groups（P=0.186,P=0.223）.Group A demonstrated significantly longer OS and PFS than Group B in the following subgroups： female patients,patients with lesions in the right half of the colon,and those who received first-line treatment（P〈0.05）.In the subgroup of elderly patients（age〉65 years）,the OS in Group A was longer than that in Group B（P〈0.05）.Conclusion： IM could prolong the survival of patients with m CRC.（Registry No.Chi CTR-IOR-17010497）展开更多
In recent years,the real-world studies(RWS)have attracted extensive attention,and the realworld evidence(RwE)has been acceptedto support the drug development in Chinaand abroad.However,there is stll a lack of standard...In recent years,the real-world studies(RWS)have attracted extensive attention,and the realworld evidence(RwE)has been acceptedto support the drug development in Chinaand abroad.However,there is stll a lack of standards for the evaluation of the quality of RWE.It is necessary to formulate a quality evaluation and reporting specification for RWE especially in traditional Chinese medicine(TCM).To this end,under the guidance of China Association of Chinese Medicine,the Quality Evaluation and Reporting Specification for Real-World Evidence of Traditional Chinese Medicine(QUERST)Group,including 24 experts(clinical epidemiologists,clinicians,pharmacologists,ethical reviewerand statisticians),was established to develop the specification.This specification contains the listing of classification of RWS design and RWE,the general principles and methods of RWE quality evaluation(26 tools or scales),25 types of bias in RWS,the special considerations in evaluating the quality of RWE of TCM,and the 19 reporting standards of RWE.This specification aims to propose the quality evaluation principles and key points of RWE,and provide guidance for the proper use of RWE in the development of TCM new drugs.展开更多
基金Supported by National Natural Science Foundation of China(No.81373824)Beijing Health Development Research Project(No.2016-1-4147)Project of the Chinese Academy of Traditional Chinese Medicine(No.ZZ070854)
文摘Objective： To investigate the efficacy of integrated Chinese and Western medicine（IM） in the treatment of metastatic colorectal cancer（m CRC） in a cohort study.Methods： The survival outcome of patients receiving IM was compared with that of patients receiving Western medicine alone.The study design was adopted with ＂continuous administration of Chinese medicine for 3 months＂ as the exposure factor.Patients who met this exposure factor were assigned to the IM cohort（Group A,110 patients）.Patients who did not meet this exposure factor were assigned to the Western medicine cohort（Group B,225 patients）.The overall survival（OS）,progression-free survival（PFS）,and 1 st year,2 nd year,and 3 rd year survival in the two cohorts were compared.Results： The median OS in Group A and B were 18 months [95% confidence interval（CI） 15-21] and 16 months（95% CI 14-18）,respectively,and the median PFS in Group A and B were 6 months（95% CI 4-7） and 5 months（95% CI 4-6）,respectively.No statistically significant differences were observed between the groups（P=0.186,P=0.223）.Group A demonstrated significantly longer OS and PFS than Group B in the following subgroups： female patients,patients with lesions in the right half of the colon,and those who received first-line treatment（P〈0.05）.In the subgroup of elderly patients（age〉65 years）,the OS in Group A was longer than that in Group B（P〈0.05）.Conclusion： IM could prolong the survival of patients with m CRC.（Registry No.Chi CTR-IOR-17010497）
基金the National Natural Science Foundation of China(No.82074282)NMPA Key Laboratory for Clinical Research and Evaluation of Traditional Chinese Medicine。
文摘In recent years,the real-world studies(RWS)have attracted extensive attention,and the realworld evidence(RwE)has been acceptedto support the drug development in Chinaand abroad.However,there is stll a lack of standards for the evaluation of the quality of RWE.It is necessary to formulate a quality evaluation and reporting specification for RWE especially in traditional Chinese medicine(TCM).To this end,under the guidance of China Association of Chinese Medicine,the Quality Evaluation and Reporting Specification for Real-World Evidence of Traditional Chinese Medicine(QUERST)Group,including 24 experts(clinical epidemiologists,clinicians,pharmacologists,ethical reviewerand statisticians),was established to develop the specification.This specification contains the listing of classification of RWS design and RWE,the general principles and methods of RWE quality evaluation(26 tools or scales),25 types of bias in RWS,the special considerations in evaluating the quality of RWE of TCM,and the 19 reporting standards of RWE.This specification aims to propose the quality evaluation principles and key points of RWE,and provide guidance for the proper use of RWE in the development of TCM new drugs.
